A novel vector system for gene transfer into the cornea using a partially dried plasmid expressing 18 basic fibroblast growth factor-synthetic amphiphile INTeraction-18 (SAINT-18) complex

Current Eye Research

Volumn 33, Issue 10, 2008, Pages 839-848

  Kuo, Chien Neng ^a,b   Yang, Lin Cheng ^c   Yang, Cheng Ta ^a   Chen, Miao Fen ^a,b   Lai, Chien Hsiung ^a,b   Chen, Yi Hao ^a,b   Chen, Ching Hsein ^d   Chen, Chi Hung ^d   Wu, Pei Chang ^a,b   Kou, Hsi Kung ^a,b   Tsai, Jen Chia ^a,b   Hung, Chia Hui ^e  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

^d NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^e CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Angiogenesis; Cornea; Fibroblast growth factor; Nonviral vector; SAINT

Indexed keywords

AMPHOPHILE; BASIC FIBROBLAST GROWTH FACTOR; GREEN FLUORESCENT PROTEIN; PLASMID VECTOR; SYNTHETHIC AMPHIPHILE INTERACTION 18; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMICROSCOPY; COMPLEX FORMATION; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; EYE EXAMINATION; GENE TRANSFER; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CORNEAL NEOVASCULARIZATION; CORNEAL STROMA; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; MALE; PLASMIDS; PYRIDINIUM COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; SURFACE-ACTIVE AGENTS;

EID: 53849092734     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680802382963     Document Type: Article

References (42)

1. Notting IC, Missotten GS, Sijmons B, Boonman ZF, Keunen JE, van der Pluijm G. Angiogenic profile of uveal melanoma.Curr Eye Res. 2006;31:775-785.
2. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization.J Clin Invest. 1999;103:1231-1236.
3. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.
4. Soubrane G, Cohen SY, Delayre T, Tassin J, Hartmann MP, Coscas GJ, Courtois Y, Jeanny JC. Basic fibroblast growth factor experimentally induced choroidal angiogenesis in the minipig. Curr Eye Res. 1994;13:183-195.
5. Aviles RJ, Annex BH, Lederman RJ. Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2). Br J Pharmacol. 2003;140:637-646.
6. Soubrane G, et al. Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea. Invest Ophthalmol Vis Sci. 1990;31:323-333.
7. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci. 1996;37:1625-1632.
8. Li WW, Grayson G, Folkman J, D'Amore PA. Sustained-release endotoxin. A model for inducing corneal neovascularization. Invest Ophthalmol Vis Sci. 1991;32:2906-2911.
9. Adamis AP, Meklir B, Joyce NC. In situ injury-induced release of basic-fibroblast growth factor from corneal endothelial cells. Am J Pathol. 1991;139:961-966.
10. Klein-Soyer C, Beretz A, Cazenave JP, Driot F, Maffrand JP. Behavior of confluent endothelial cells after irradiation. Modulation of wound repair by heparin and acidic fibroblast growth factor. Biol Cell. 1990;68:231-238.
11. Hayashi N, Nakayasu K, Okisaka S. Immunohistochemical localization of acidic and basic fibroblast growth factor through corneal neovascularization in vivo and in vitro. Nippon Ganka Gakkai Zasshi. 1996;100:587-591.
12. Benelli U, Bocci G, Danesi R, Lepri A, Bernardini N, Bianchi F, Lupetti M, Dolfi A, Campagni A, Agen C, Nardi M, Del Tacca M. The heparin sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. Exp Eye Res. 1998;67:133-142.
13. Van der Woude I, Wagenaar A, Meekel AA, ter Beest MB, Ruiters MH, Engberts JB, Hoekstra D. Novel pyridinium surfactants for efficient, nontoxic in vitro gene delivery. Proc Natl Acad Sci USA. 1997;94:1160-1165.
14. Akimoto M, et al. Adenovirally expressed basic fibroblast growth factor rescues photoreceptor cells in RCS rats. Invest Ophthalmol Vis Sci. 1999;40:273-279.
15. Kuo CN, Yang LC, Wu PC, Kuo HK, Kuo CJ, Tai MH. Dehydrated form of plasmid expressing basic fibroblast growth factor-polyethylenimine complex is a novel and accurate method for gene transfer to the cornea. Curr Eye Res. 2005;30:1015-1024.
16. Molina MC, Allison SD, Anchordoquy TJ. Maintenance of nonviral vector particle size during the freezing step of the lyophilization process is insufficient for preservation of activity: Insight from other structural indicators. J Pharm Sci. 2001;90:1445-1455.
17. Mahato RI. Nonviral peptide-based approaches to gene delivery. J Drug Target. 1999;7:249-268.
18. Mohan RR, Schultz GS, Hong JW, Mohan RR, Wilson SE. Gene transfer into rabbit keratocytes using AAV and lipid-mediated plasmid DNA vectors with a lamellar flap for stromal access. Exp Eye Res. 2003;76:373-383.
19. Nguyen TH, Murakami A, Fujiki K, Kanai A. Transferrin-polyethylenimine conjugate, FuGENE6 and TransIT-LT as nonviral vectors for gene transfer to the corneal endothelium. Jpn J Ophthalmol. 2002;46:140-146.
20. Shewring L, et al. A non-viral vector system for efficient gene transfer to corneal endothelial cells via membrane integrin. Transplantation. 1997;64:763-769.
21. Hudde T, et al. Activated polyamidoamine dendrimer as non-viral vector for gene transfer to the corneal endothelium. Gene Ther. 1999;6:939-943.
22. Audouy S, Molema G, de Leij L, Hoekstra D. Serum as a modulator of lipoplex-mediated gene transfection: Dependence of amphiphile, cell type, and complex stability. J Gene Med. 2000;2:465-476.
23. Haider HK, Elmadbouh I, Jean-Baptiste M, Ashraf M. Nonviral vector gene modification of stem cells for myocardial repair. Mol Med. 2008;14:79-86.
24. Gaspar HB, Howe S, Thrasher AJ. Gene therapy progress and prospects: Gene therapy for severe combined immunodeficiency. Gene Ther. 2003;10:1999-2004.
25. Kawasuji M. Therapeutic angiogenesis for ischemic heart disease. Ann Thorac Cardiovasc Surg. 2002;8:59-61.
26. Chang LK, et al. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci. 2004;101:11658-11663.
27. Friesel R, Maciag T. Fibroblast growth factor prototype release and fibroblast growth factor signaling. Thromb Haemostas. 1999;82:748-754.
28. Dow JK, DeVere White RW. Fibroblast growth factor 2: Its structure and properties, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology. 2000;55:800-806.
29. Parker AL, Eckley L, Singh S, Preece JA, Collins L, Fabre JW. (LYS)(16)-based reducible polycations provide stable polyplexes with anionic fusogenic peptides and efficient gene delivery to post mitotic cells. Biochim Biophys Acta. 2007;1770:1331-1337.
30. Ritter T, Yang J, Dannowski H, Vogt K, Volk HD, Pleyer U. Transplant effects of interleukin-12p40 gene transfer on rat corneal allograft survival. Immunol. 2007;18:101-107.
31. Gong N, Pleyer U, Vogt K, Anegon I, Flügel A, Volk HD, Ritter T. Local overexpression of nerve growth factor in rat corneal transplants improves allograft survival.Invest Ophthalmol Vis Sci. 2007;48:1043-1052.
32. Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh DA. Differential αv integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol. 2003;162:933-943.
33. Cheng HC, Yeh SI, Tsao YP, Kuo PC. Subconjunctival injection of recombinant AAV-angiostatin ameliorates alkali burn induced corneal angiogenesis. Mol Vis. 2007;13:2344-2352.
34. Lai LJ, Xiao X, Wu JH. Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model. J Biomed Sci. 2007;14:313-322.
35. Wu PC, Liu CC, Chen CH, Kou HK, Shen SC, Lu CY, Chou WY, Sung MT, Yang LC. Inhibition of experimental angiogenesis of cornea by somatostatin. Graefes Arch Clin Exp Ophthalmol. 2003;241:63-69.
36. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999;285:245-248.
37. Gabison E, Chang JH, Hernandez-Quintela E, Javier J, Lu PC, Ye H, Kure T, Kato T, Azar DT. Anti-angiogenic role of angiostatin during corneal wound healing. Exp Eye Res. 2004;78:579-589.
38. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082-4085.
39. Epstein RJ, Hendricks RL, Stulting RD. Interleukin-2 induces corneal neovascularization in A/J mice. Cornea. 1990;9:318-323.
40. Chollet P, Favrot MC, Hurbin A, Coll JL. Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J Gene Med. 2002;4:84-91.
41. S. Audouy, G. Hosper, et al. In vivo evaluation of the safety and toxicity of a new cationic liposome formulation for human gene therapy applications. AACR Meeting, April 10-14, 1999.
42. S. Audouy, et al. Serum as a modulator of lipoplex-mediated gene transfection: Dependence of amphiphile, cell type, and complex stability. J Gene Med. 2000;2:465-476.